drugset / Trial / NCT06186440
Cisplatin Plus Temozolomide Compared With Temozolomide in Patients With MGMT Promotor Unmethylated Glioblastoma
RandomizedParallel-groupSingle-blindTreatment
Summary
Temozolomide provided significant and clinically meaningful benefit in MGMT gene promoter methylation glioblastoma. However, in unmethylated patients, the effect of Temozolomide is limited. The aim of this study is to compare the effect of Cisplatin plus Temozolomide and Temozolomide in patients with MGMT gene promoter unmethylation glioblastoma
Timeline
- Start
- 2024-01-01
- Primary completion
- 2024-12-01
- Completion
- 2025-01-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 20 mg/m2 | — |
| Subject | Temozolomide | Small molecule | 150 mg/m2 | — |
| Subject | Temozolomide | Small molecule | 200 mg/m2 | — |